Ligand Pharmaceuticals Incorporated (LGND) — ESG & Values Scores

Environment story

Ligand demonstrates moderate environmental commitment with disclosed renewable energy initiatives and EHS policy frameworks, but lacks comprehensive Scope 1, 2, and 3 emissions reporting. The company completed a $2.6 million solar investment at Kansas University Innovation Park in early 2025 and established ESG-focused charitable programs. However, no net-zero target year, formal emissions reduction trajectory, or supply-chain carbon accounting have been disclosed in the 10-K filing. The absence of quantified environmental metrics and third-party verification prevents higher scoring.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Solar Investment at Kansas University Innovation Park

Completed $2.6 million solar energy infrastructure investment in early 2025

Direct reduction in Scope 2 emissions; physical decarbonization infrastructure (not offset-based)
Environmental, Social and Governance Charitable Donations

ESG-related charitable donations and program evolution from ESG-focused outreach committees in 2025

Community environmental engagement; strategic alignment with ESG priorities
Environmental, Health and Safety (EHS) Policy Framework

Commitment to safe and healthy workplace, environmental excellence, pollution reduction, injury prevention, and regulatory compliance

Operational risk mitigation; governance of environmental and occupational hazards

Social story

Ligand demonstrates solid social practices with a balanced workforce composition and established HR benefit structures. The company reports 51% female and 49% male workforce, with 21% Asian and 11% Hispanic representation as of December 31, 2025. CEO-to-median-worker pay ratio is not disclosed. The company emphasizes competitive compensation, equity awards, subsidized health insurance, 401(k) matching, tuition assistance, and paid time off. No documented union-suppression activities, major strikes, or supply-chain human-rights controversies are disclosed. However, limited disclosure on executive-to-median-worker pay ratio and leadership diversity percentages prevents higher scoring.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Diversity and Inclusion Programs

Company-wide focus on extending diversity and inclusion initiatives across workforce; recognition of workforce diversity benefits; 51% female, 49% male, 21% Asian, 11% Hispanic workforce composition

Promotes inclusive workplace culture and varied perspectives in decision-making
Competitive Compensation and Benefits

Equity awards via 2002 Stock Incentive Plan, subsidized health insurance, 401(k) matching, tuition assistance, and paid time off

Employee retention and engagement; competitive positioning in labor market
Flexible Work Environment

Hybrid in-office and virtual work model to support partner and client service delivery

Enhanced employee work-life balance and operational flexibility
Annual Employee Engagement Survey

Regular feedback collection on belonging, learning, recognition, compensation, and wellbeing; action plans developed from survey insights

Continuous improvement of human capital management practices
Discrimination Prevention and Reporting

Commitment to inclusive environment free from discrimination; multiple reporting avenues including confidential hotline; prompt investigation of reports

Risk mitigation for workplace harassment and discrimination; employee trust in reporting mechanisms

Governance story

Ligand demonstrates adequate governance practices with emphasis on patent enforcement and regulatory compliance. The company maintains documented board commitment to ESG policies and stated focus on shareholder and employee engagement. Board independence percentage, share structure specifics, and lobbying expenditures are not disclosed in the 10-K. The company faces material intellectual property litigation risks (Nexterone, Evomela, and Kyprolis generic challenges) and active regulatory oversight typical of biopharmaceutical firms. No evidence of dual-class share structures, antitrust proceedings, or governance fines is disclosed. The absence of transparency on board composition and lobbying activities limits scoring.

Criticisms on file

Patent Infringement Litigation (Nexterone)
Source: LGND 10-K 2025: CyDex and Baxter filed suit in 2025 against PH Health Ltd., Par Health USA, Endo USA, Inc., Endo Operations Limited, and Endo, Inc. for generic Nexterone patent infringement; defendants have filed Answer and discovery has started
Patent Infringement Litigation (Evomela)
Source: LGND 10-K 2025: CyDex and Acrotech filed suit in 2025 against Gland Pharma Limited for generic Evomela patent infringement; three Orange Book-listed patents asserted with latest expiration May 2030
Generic Competition (Kyprolis)
Source: LGND 10-K 2025: Amgen previously settled Kyprolis patent litigation with multiple parties; Breckenridge Pharmaceuticals' generic launch publicly reported as confidential date in 2027 or sooner
Generic Competition Settlement (Evomela)
Source: LGND 10-K 2025: Settlement agreement with Teva and Acrotech Biopharma permits Teva to market generic Evomela in United States starting June 1, 2026 or earlier under certain circumstances

Disclosed initiatives

ESG Policies and Practices Commitment

Corporate governance highlights focused on environmental sustainability, positive social impact, and good corporate governance; proactive shareholder and employee engagement in 2026

Strategic alignment with stakeholder expectations; formal governance framework
Patent Protection and IP Enforcement

Active defense of patent rights through litigation (Nexterone vs. generic manufacturers, Evomela vs. Gland Pharma, Kyprolis defense); Orange Book listings for multiple products; robust IP portfolio across multiple platforms

Protection of royalty streams and product competitiveness; revenue defense against generic competition
Regulatory Compliance Framework

Documented commitment to FDA regulations, cGMP compliance, post-market surveillance, and adverse event reporting for pharmaceutical products

Operational risk mitigation; avoidance of regulatory enforcement actions
Investor Information Transparency

Regular SEC filings (10-K, 10-Q, 8-K), website disclosure of financial and ESG information, use of X and investor relations channels for material non-public information disclosures

Compliance with Regulation FD; stakeholder communication and transparency

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Ligand Pharmaceuticals Incorporated. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Ligand Pharmaceuticals Incorporated in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)